Journal of Clinical Oncology, Vol 23, No 26 (September 10), 2005: pp. 6351-6357
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.05.012
Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma
Izidore S. Lossos
From the Sylvester Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL
Address reprint requests to Izidore S. Lossos, MD, University of Miami, Sylvester Comprehensive Cancer Center, Department of Hematology and Oncology, 1475 NW 12th Ave (D8-4), Miami, FL 33136; e-mail: ilossos{at}med.miami.edu.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous clinicopathologic entity accounting for 30% of non-Hodgkin's lymphomas. The pathogenesis of DLBCL is complex and heterogeneous. Recent studies using analysis of global gene expression with DNA microarrays and the classical molecular approaches demonstrate presence of several DLBCL subtypes characterized by different cells of origin, cytogenetic and molecular aberrations, and distinct pathogenesis. This review summarizes the progress in understanding of DLBCL biology and presents a state-of-the-art overview of DLBCL molecular pathogenesis.
Supported by Grant No. RO1 CA109335 from the United States Public Health Service National Institutes of Health and the Dwoskin Family Foundation.
Author's disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
W. W.L. Choi, D. D. Weisenburger, T. C. Greiner, M. A. Piris, A. H. Banham, J. Delabie, R. M. Braziel, H. Geng, J. Iqbal, G. Lenz, et al.
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
Clin. Cancer Res.,
September 1, 2009;
15(17):
5494 - 5502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Blood,
October 1, 2008;
112(7):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Salaverria, A. Zettl, S. Bea, E. M. Hartmann, S. S. Dave, G. W. Wright, E.-J. Boerma, P. M. Kluin, G. Ott, W. C. Chan, et al.
Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma
Haematologica,
September 1, 2008;
93(9):
1327 - 1334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. C.-H. Chiu, Q. Lan, B. J. Dave, A. Blair, S. H. Zahm, and D. D. Weisenburger
The Utility of t(14;18) in Understanding Risk Factors for Non-Hodgkin Lymphoma
J Natl Cancer Inst Monographs,
July 1, 2008;
2008(39):
69 - 73.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. C.-H. Chiu, B. J. Dave, A. Blair, S. M. Gapstur, J. S. Chmiel, A. J. Fought, S. H. Zahm, and D. D. Weisenburger
Cigarette Smoking, Familial Hematopoietic Cancer, Hair Dye Use, and Risk of t(14;18)-defined Subtypes of Non-Hodgkin's Lymphoma
Am. J. Epidemiol.,
March 15, 2007;
165(6):
652 - 659.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al.
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Blood,
March 1, 2007;
109(5):
1857 - 1861.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|